Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme therapy presented as an injectable solution for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyrias in patients experiencing metabolic attacks that can cause severe neurovisceral symptoms. These conditions arise from deficiencies in the heme biosynthetic pathway, leading to accumulation of toxic precursors.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialized clinical centres worldwide through regulated distribution networks.

Normosang is used in the management of acute hepatic porphyria disorders by supplying exogenous heme. Acute intermittent porphyria: reduces neurotoxic porphyrin precursor buildup during attacks, improving abdominal pain and neurological symptoms. Hereditary coproporphyria: alleviates acute manifestations by down‑regulating hepatic ALAS1 activity and limiting precursor accumulation. Variegate porphyria: helps control acute episodes through heme supplementation, decreasing severity of abdominal and neurovisceral complaints.

Administration of Normosang may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Infusion site pain: discomfort at the injection site. - Nausea: feeling of sickness during or after infusion. - Headache: mild to moderate cranial pain. - Fever or chills: transient rise in body temperature. Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure. - Anaphylaxis: severe allergic reaction with respiratory compromise. - Hemolysis: destruction of red blood cells leading to anemia.

Prior to using Normosang, clinicians should observe several precautionary measures to ensure patient safety. - Monitor liver function: assess hepatic enzymes before and during therapy. - Assess iron status: avoid excess iron accumulation with repeated dosing. - Evaluate for hypersensitivity: discontinue if signs of allergic reaction appear. - Infuse slowly: avoid rapid administration to reduce cardiovascular stress. - Use cautiously in cardiovascular disease: monitor blood pressure and heart rate. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes. Major Interactions (Avoid): - Concurrent heme products: may cause iron overload. - Porphyrinogenic drugs (e.g., barbiturates, sulfonamides): can exacerbate porphyria. - Iron chelators: may interfere with hemin’s iron content. Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk. - CYP450 inducers: potential alteration of heme synthesis. - Vitamin D analogs: may affect calcium metabolism.